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PURPOSE: Noninvasive prenatal screening (NIPS) using cell-free DNA has transformed prenatal care. Belgium was the first country
to implement and fully reimburse NIPS as a first-tier screening test offered to all pregnant women. A consortium consisting of all
Belgian genetic centers report the outcome of two years genome-wide NIPS implementation.
METHODS: The performance for the common trisomies and for secondary findings was evaluated based on 153,575 genome-wide
NIP tests. Furthermore, the evolution of the number of invasive tests and the incidence of Down syndrome live births was
registered.
RESULTS: Trisomies 21, 18, and 13 were detected in respectively 0.32%, 0.07%, and 0.06% of cases, with overall positive predictive
values (PPVs) of 92.4%, 84.6%, and 43.9%. Rare autosomal trisomies and fetal segmental imbalances were detected in respectively
0.23% and 0.07% of cases with PPVs of 4.1% and 47%. The number of invasive obstetric procedures decreased by 52%. The number
of trisomy 21 live births dropped to 0.04%.
CONCLUSION: Expanding the scope of NIPS beyond trisomy 21 fetal screening allows the implementation of personalized genomic
medicine for the obstetric population. This genome-wide NIPS approach has been embedded successfully in prenatal genetic care
in Belgium and might serve as a framework for other countries offering NIPS.
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INTRODUCTION
Noninvasive prenatal screening (NIPS) by sequence analysis of
cell-free DNA (cfDNA) fragments circulating in the blood of
pregnant women enables the detection of fetal aneuploidies.1–3
With test sensitivities ranging between 92% and 99% for the
viable trisomies 21, 18, and 13 and a specificity of >99%, NIPS
outperforms traditional combined first trimester screening
(cFTS),4–6 reducing the amount of invasive prenatal tests and
the concurrent risk of procedure-related pregnancy complications.
Hence, different professional societies advocated the implementa-
tion of NIPS for high and intermediate risk pregnancies.7–10 The
test was swiftly adopted by the community and has globally
transformed prenatal care.11 Nevertheless, implementation,
uptake and testing approaches vary largely among and within
countries.12
Belgium was the first country to implement and fully reimburse
NIPS as a first-tier screening test, offering NIPS virtually for free to
all pregnant women. With nationwide implementation of NIPS,
reimbursement for serum biochemical assays was phased out and
consequently cFTS disappeared from routine pregnancy manage-
ment.13 Fetal ultrasound is still performed to measure the nuchal
translucency (NT) and identify fetal malformations, both indicators
for additional genetic counseling and invasive genetic testing.
Prenatal care and prenatal genetic testing monitor the health
and aim to improve the outcome for mother and fetus. Despite
being the most common genetic cause of birth defects, trisomy 21
constitutes only one of many genetic disorders affecting placental,
fetal, and neonatal development and pregnancy outcome. Since
all neonatal and invasive prenatal genetic testing in Belgium is
performed at one of the eight genetic centers, introduction of
NIPS was considered an opportunity to broaden the scope of
traditional prenatal testing by implementing personalized geno-
mic medicine for the obstetric population and as a consequence
improve overall prenatal care.
The Belgian Advisory Committee on Bioethics advised that
secondary findings, i.e., findings beyond the common trisomies,
detected during genome-wide NIPS should be reported when
clinically significant.14 In case this information may lead to
preventive or therapeutic intervention, it is important to share it
with the patient and provide genetic counseling. The failure to do
so may be construed as serious negligence. This prompted the
Belgian Society for Human Genetics to issue guidelines on
reporting secondary findings.15 Secondary findings are reported
if (1) considered technically valid, (2) there is validated evidence
on the associated phenotype, and (3) considered clinically relevant
and actionable. Because of the controversy about the validity and
clinical utility of NIPS as a screening tool for fetal sex chromosome
abnormalities, they are not reported. Since the majority of the
cfDNA analyzed by NIPS is of maternal origin, genome-wide NIPS
can also reveal maternal copy-number variations (CNVs).
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According to the Belgian NIPS guidelines and in accordance with
the postnatal genomic testing guidelines of the American College
of Medical Genetics and Genomics,16 clinically relevant and
actionable maternal imbalances are reported.
Here, a consortium consisting of all Belgian genetic centers
presents the performance of genome-wide NIPS for both primary
and secondary findings as well as the impact on the obstetric




Peripheral blood samples were collected in cell-free DNA BCT tubes
(Streck, Omaha, NE, USA), cell-free DNA collection tubes (Roche
Diagnostics, Germany), or PAXgene blood circulating cfDNA (ccfDNA)
tubes (QIAGEN GmbH, Germany) from 12 weeks of gestation onward.
Clinical genetic laboratories from the eight Belgian genetic centers
performed genome-wide NIPS. Standard centrifugation methods were
used for plasma isolation. cfDNA extraction was performed using the
QIAamp Circulating Nucleic Acid Kit (Qiagen), the Maxwell HT cfDNA kit
(Promega), or the VeriSeq NIPT solution v2 (Illumina) according to the
manufacturer’s recommendations. Library preparation for genome-wide
shallow genome sequencing was performed using the Kapa HyperPlus
preparation kit (Kapa Biosystems); TruSeq ChIP, TruSeq DNA Nano library
preparation kit or the VeriSeq NIPT Solution v2 (Illumina); NEXTflex Cell-free
DNA-seq kit or NEXTflex Rapid DNA-Seq kit 2.0 (Bioo Scientific). Next-
generation sequencing was performed with either the Ion Proton system
(ThermoFisher scientific) or the VeriSeq NIPT v2 solution, HiSeq1500,
HiSeq2500, HiSeq3000, HiSeq4000, Novaseq6000, NextSeq500 or
NextSeq550 sequencer (Illumina). Genome-wide genomic representation
profiling and interpretation was performed using the VeriSeq NIPT Assay
Control Software v2.0.0 (Illumina) or as previously described.17–19
Post-test counseling
Women with a low-risk NIPS result were informed by their obstetric care
professional or via the patients’ online medical files. The follow-up
procedure for a high-risk result depended on the type of aberration found.
In case of a high risk for a common trisomy (21, 18, or 13), women were
informed by their obstetrician, followed by invasive prenatal diagnostics if
desired. All women at high risk for a secondary finding were referred to
and counseled by a clinical geneticist.
Follow-up testing
When cfDNA profiling indicated the presence of a fetal chromosomal
abnormality, pregnant women were offered follow-up by standard invasive
prenatal diagnosis.
CNV analysis was performed on DNA extracted from chorionic villus
sampling (CVS) or amniotic fluid (AF) using the Agilent ISCA 60 K or 44 K
array (Agilent), Cytoscan 750 K array (Affymetrix), HumanCytoSNP-12 v2.1
BeadChip kit (Illumina), or by shallow genome sequencing (CNVSeq).
Fluorescence in situ hybridization (FISH) was performed following standard
procedures. Subsequently, when a discrepancy between the NIPS and the
invasive genetic test result was detected, women were requested to
donate the placenta upon delivery.
A trisomic embryo can develop into a normal disomic fetus by loss of
one of the three chromosomes, a phenomenon called trisomy rescue. In
one third of trisomy rescue events this results in uniparental disomy (UPD).
UPD testing on amniotic fluid was performed when NIPS indicated a
trisomy for chromosomes 6, 7, 11, 14, 15, or 20, as UPD for one of these
chromosomes is known to be associated with developmental disorders.20
UPD was tested using the HumanCytoSNP-12 v2.1 BeadChip kit (Illumina),
polymorphic short tandem repeat (STR) analysis (Promega), or
methylation-specific multiplex ligation-dependent probe amplification
(MS-MLPA) probemix ME032-A1 (MRC Holland).
If a maternal constitutional CNV was considered (1) clinically relevant
and (2) technically valid based on the NIPS data, this maternal CNV was
immediately included in the NIPS report. If the maternal constitutional CNV
was classified as clinically relevant but was not considered as technically
valid based on the NIPS data, this maternal CNV was first confirmed by an
independent analysis on maternal white blood cells, obtained from the
stored buffy coats of the NIPS blood sample. Maternal constitutional CNVs
were confirmed by FISH (standard protocol), chromosomal microarray
analysis, or shallow genome sequencing as previously described.18,21 The
timeframe for this confirmation was 1 week on average. The implementa-
tion of NIPS and the interpretation of both fetal and maternal incidental
findings were approved by the institutional ethics review board and are
consented for by both the referring physician and the pregnant women.
RESULTS
NIPS performance in the general obstetric population
Between 1 July 2017 and 30 June 2019, the National Institute for
Health and Disability Insurance (RIZIV-INAMI) registered 188,330
NIPS analyses. Since the large majority of NIPS analyses are
performed at 12 weeks of gestation and it is known that about
2.5% of 12-week pregnancies result in miscarriage, the estimated
number of NIP-screened live births is 183,621.22 Since in 2018,
117,800 and in 2019 115,565 live births were registered, 78.7% of
the pregnant women opted for NIPS, a similar percentage when
compared to the uptake of cFTS before NIPS.23 The mean maternal
age at delivery in 2018 and 2019 was 30.7 years and 30.8 years,
respectively.
Of all registered NIP tests, 153,575 pregnant women (81.5%)
received NIPS in one of the Belgian genetic centers, consisting of
150,805 (98.2%) singleton pregnancies and 2,770 (1.8%) twin
pregnancies. Higher-order pregnancies were not included in this
study. A NIPS result could be reported to 99.3% of women. For
0.7% of the pregnancies the result remained inconclusive even
after repeated analysis. This failure rate is equal or lower
compared with other studies.24
Trisomies 21, 18, and 13 were detected in respectively 494
(0.32%), 115 (0.07%), and 91 (0.06%) cases. Results of invasive
testing following a positive NIPS for trisomy 21, 18, and 13 could
be collected for 394 (79.8%), 91 (79.1%), and 82 (90.1%)
pregnancies and confirmed a fetal trisomy in 364, 77, and 36
cases, respectively. Of note, there were no false positives among
11 dizygotic twin pregnancies for which invasive follow-up data
were available. This results in positive predictive values (PPVs) of
92.4% for trisomy 21, 84.6% for trisomy 18, and 43.9% for trisomy
13 (Table 1). These results are largely consistent with published
data for both high-risk and general obstetric populations.4,25
In case of a discrepancy between the noninvasive and the
invasive test, women were requested to participate in a follow-up
study allowing placental analysis after delivery to determine
whether confined placental mosaicism (CPM) could explain the
false positive outcome. Placental tissue could be obtained for
respectively 5, 3, and 16 apparent false positive trisomies 21, 18,
and 13; placental mosaicism was observed in 3, 1, and 8 cases. This
result indicates that at least half of the false positive NIPS results
can be explained by CPM and are not caused by technical issues.
False negative results for trisomies 21, 18, and 13 were reported
in 4, 2, and 0 cases, respectively. Because all prenatal/neonatal
cytogenetic testing in Belgium is performed in one of the genetic
centers involved in this study, it is unlikely a false negative is
missed. One of the four trisomy 21 false negatives presented in
only 7% of placental cells, while the trisomy was found in 100% of
fetal cells as well as in 75% of umbilical cord cells. One of the two
false negatives for trisomy 18 was shown to be mosaic, with
trisomy 18 present in about 60% of the placental cells. Placental
follow-up data was not available for the remaining four false
negatives. There were no false negatives among 2,029 dichorionic
diamniotic (DCDA) twin samples showing that NIPS has a high
sensitivity for twin pregnancies as well.
Genomic medicine for the obstetric population
A total of 350 (0.23%) pregnancies were reported with a rare
autosomal fetal aneuploidy, of which 339 pregnancies presented
with a rare autosomal trisomy (RAT) (Fig. 1). As in other cohorts,25–
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27 the most frequent RAT was trisomy 7 (39.2%), followed by
trisomy 20 (11.5%), 8 (8.8%), 16 (8.3%), 22 (6.2%), and 15 (5.3%). In
78.5% (266/339) of RATs, an invasive genetic test result was
obtained. Eleven RATs turned out positive in the fetus: trisomy 2
(n= 1), 8 (n= 3), 9 (n= 1), 16 (n= 4), and 22 (n= 2), resulting in a
positive predictive value of 4.1%. The remaining 255/266 (95.9%)
RATs showed no fetal imbalance following invasive or postnatal
genetic testing. Based on the ratio between the theoretical versus
the observed chromosomal z-scores in function of fetal fraction,
the test allows to predict CPM.28 This analysis suggested that the
large majority of false positive RATs are the result of CPM and this
was strengthened by placental or chorionic villus biopsy: for 51 of
the apparently false positive RATs with follow-up, placental
mosaicism was confirmed in over half of the cases (28/51; 54.9%).
UPD testing was performed in 64 pregnancies: trisomy 7 (n=
43), 11 (n= 2), 14 (n= 9), 15 (n= 5), and 20 (n= 5). Three UPDs
were detected: 1 for trisomy 7 and 2 for trisomy 15. Hence, UPD
was observed in 4.7%.
Eleven pregnancies presented with a monosomy: monosomy 13
(n= 1), 15 (n= 1), 16 (n= 2), 18 (n= 4) and 21 (n= 3). For six
monosomies, an invasive prenatal test was performed; none was
confirmed.
In 0.07% (109/153,575) of the pregnancies, NIPS was
suggestive of the presence of a fetal segmental imbalance. We
observed 11 potential genomic disorders, 14 whole chromoso-
mal arm gains and 1 loss, 9 interstitial gains and 30 losses, 17
terminal segmental gains and 19 losses, 5 likely unbalanced
translocations (both a terminal deletion and terminal duplica-
tion), and 3 complex rearrangements (Table S1, Figure S1). Fetal
or postnatal follow-up data was available for 92 cases (84.4%). Of
those, 43 were confirmed to be true positives, resulting in a PPV
of 47%. Two imbalances that were not confirmed in the fetus
were shown to be present in the placenta. Eight additional
imbalances turned out not to be fetal but (mosaic) maternal in
origin, as shown by fluorescent in situ hybridization (FISH) or
chromosomal microarray on DNA extracted from the maternal
white blood cells.
Clinically relevant maternal CNVs were reported in 0.32% of the
cases (Fig. 2). NIPS profiles reminiscent of the presence of
maternal cancers29 were detected and confirmed in 12 cases
(0.008%). Other reported maternal secondary findings included
heterozygosity for pathogenic CNVs related to highly penetrant
dominant or X-linked disorders such as cancer predisposition
syndromes or Duchenne muscular dystrophy,30 respectively.
Impact on the number of invasive tests
The high specificity of NIPS has significantly reduced the number
of amniocenteses and CVS procedures worldwide.31–33 Also in
Belgium, a decline in invasive obstetric procedures has been
registered by the RIZIV-INAMI between 2013, the last year before
the nonreimbursed NIPS was introduced in Belgium, and 2018, the
first full year following generalized introduction of reimbursed
NIPS. During this period, the absolute number of invasive obstetric
procedures performed dropped from 6,279 to 3,047 (Fig. 3). When
normalized based on the number of live births, a number linearly
related with the number of pregnancies, this corresponds to a
decrease of 52%. Although the overall number of invasive tests
Table 1. Performance of noninvasive prenatal screening (NIPS) as a first-tier screening test.
Incidence Sensitivity Specificity PPV NPV
% % 95% CI % 95% CI % 95% CI % 95% CI
Trisomy 21 0.32 98.91 97.24–99.58 99.98 99.97–99.99 92.39 89.34–94.61 100.00 99.99–100.00
Trisomy 18 0.07 97.47 91.23–99.30 99.99 99.98–99.99 84.62 75.82–90.61 100.00 100.00–100.00
Trisomy 13 0.06 100.00 90.36–100.00 99.97 99.96–99.98 43.90 33.67–54.68 100.00 100.00–100.00
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Fig. 1 Incidence of rare autosomal trisomies. Reported autosomal trisomies subdivided by outcome of the follow-up: true positive (green),
confined placental mosaicism (yellow), negative on both amniotic fluid and placenta biopsy (red), negative on amniotic fluid but no placenta
biopsy available (blue), no invasive follow-up (gray).
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significantly decreased, the actual figure outnumbers the number
of invasive tests predicted on the basis of the trisomy 21 incidence
by 440.23 This can be explained by the invasive follow-up of
inconclusive results and secondary findings as well as improved
ultrasound performance.
With the introduction of NIPS as a first-tier screening test,
invasive tests because of advanced maternal age or abnormal
cFTS largely ceased to exist. The increased specificity of NIPS
compared with cFTS screening is clearly reflected by the drop in
the relative ratio of invasive tests performed in case of advanced
maternal age or abnormal cFTS in the pre-NIPS era (before
November 2013) from 52.8% to 26.2% of invasive follow-up
performed for a positive NIPS result in the first-tier NIPS era (after
July 2017). The ratio of invasive tests performed for indications not
eligible for NIPS (e.g., ultrasound anomalies, infections, familial
history) increased from 47.2% pre-NIPS to 73.8%.
Incidence of Down syndrome live births
One of the unanswered questions arising from the widespread
implementation of NIPS for trisomy 21 detection is its effect on
terminations of pregnancy and hence the number of children
born with Down syndrome.34,35 We collected all neonatal trisomy
21 genetic test results and observed a decline from 77 trisomy 21
live births (0.06% of live births) in 2014 to 52 trisomy 21 live births
(0.04% of live births) in 2018. Since there are no plausible
biological/demographic changes in the general obstetric popula-
tion that could point to a significant impact on the ratio of the
frequency of trisomy 21–related spontaneous miscarriages to the
trisomy 21 incidence during pregnancy over this four-year period,
this decline might be explained by a combination of the
decreased number of false negatives with NIPS compared with
cFTS and the choice for pregnancy termination for the large
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Fig. 2 Percentage of pregnancies with a fetal or maternal imbalance from first-tier genome-wide NIPS. The incidence (Y-axis) of each of
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Fig. 3 Number of invasive procedures normalized per 1,000 live births performed from 2013 to 2018 in Belgium (RIZIV-INAMI registration).
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DISCUSSION
Several professional societies raised awareness that broadening
the scope of NIPS requires careful considerations of proper
counseling of the pregnant women.36 The Belgian context
provides a unique setting: genetic counseling is fully reimbursed
for all and the geneticists as test providers collaborate closely with
the obstetric community. When a fetal or maternal genetic lesion
is detected, the obstetrician is informed and the pregnant woman
is invited for genetic counseling. This end-to-end multidisciplinary
approach creates a sense of control and confidence among
doctors and patients on the national implementation of genome-
wide NIPS as a first-tier screening test for all pregnant women as
standard of care.
While the association of trisomy 16 with a higher risk of adverse
pregnancy outcome is well established,37 this association remains
controversial for the other RATs.25,26,37 When a RAT is detected in
CVS, it is attributable to CPM in 97% of the cases.38 The low PPV
for RATs confirms that most RATs are confined to the placenta.
CPM in which both mesenchymal and cytotrophoblast cells
contain the RAT has been proven to be associated with
complications in pregnancy.39 Genome-wide NIPS studies suggest
a higher incidence of adverse pregnancy outcomes when a RAT is
detected.26 Overall, the clinical consequences of most RATs are
poorly mapped and broad scale reporting may require larger-scale
studies on associated obstetric complications to determine which
RATs need follow-up and could provide obstetric relevant
information.25,26 Equally, the follow-up of segmental imbalances
requires further refinement. For known balanced translocation
carriers, the detection of the associated unbalanced translocation
in the fetus is virtually diagnostic. For larger segmental imbalances
resulting in more severe developmental disorders as compared
with Down syndrome, an invasive test seems warranted despite
the lower PPV.
There are clinical and societal challenges remaining that need
to be addressed. The emotional distress caused by reporting
secondary findings requires attention. All pregnant women
undergoing NIPS are informed during pretest counseling that, in
rare cases, genome-wide NIPS can also reveal other clinically
relevant findings that will be reported. There are concerns that
women may be insufficiently prepared for the eventual diagnosis
of a fetus with a serious disorder or a personal health issue of
which they were unaware.36 Monitoring the understanding of
couples about the test, the impact on societal pressure for taking a
NIPS test, the free choice for a pregnancy interruption after a
positive NIPS, and the acceptance of children with Down
syndrome40,41 would be valuable. To improve future reporting,
better national pregnancy and birth registries would be
welcomed.
The implementation of NIPS as a first-tier screening test remains
restricted to a handful of countries,12 due to the predicted higher
cost for health care and reduced PPV. This two-year experience
with national publicly funded first-tier NIPS has not only
demonstrated a high PPV for trisomy 21 detection in the general
population, but also met expectations when it comes to the
predicted cost efficiency for the health-care system.23 Broadening
of the scope by leveraging genomic medicine beyond trisomy
21 screening provides additional societal and health economic
benefits. With further reductions in sequencing costs and
increasing resolution, the societal expectations to detect fetal
and maternal genetic variants in cfDNA are likely to increase. We
expect that the development of consensus guidelines among
professional societies and thoughtful follow-up of both primary
and secondary findings by genetic professionals provides a proper
framework for future prenatal genetic care.
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